KSA & UAE Skincare Launch

Top-3 Manufacturer + Formula Shortlist

White-Label Skincare Brand Strategy

Clinical Formulations • Regulatory Compliance • Market Entry

Generated:

Project Team: Anabta Research

Top-3 Strategic Pairings

1

COSMAX + Brightening Serum (F-B1)

Why This Pairing

Clinical backbone (TXA 3-5% + Niacinamide 4-5%) aligns with market demand for "visible results" and simple kits. COSMAX brings ISO 22716, MUI Halal certification, and proven UVA/formulation expertise for future PA++++ sunscreen expansion.

Expected Benefits

Risk & Mitigation

Higher MOQs typical of Tier-1 ODMs; Arabic labeling requires local partners. Mitigation: Partner with KSA/UAE label specialists; negotiate flexible initial runs.

Next 3 Actions

  1. 1. RFQ + NDA with actives brief (TXA 5% + Nia 5% + KA 2%); request 40°C accelerated stability
  2. 2. Build Arabic/English label per GSO 1943; lock claims to "clinically tested"
  3. 3. Prepare Montaj/ECAS (UAE) then eCosma (KSA) dossiers
2

Kolmar + Retinoid Anti-Aging Serum (F-A1)

Why This Pairing

Retinol 0.3% or retinaldehyde 0.1% requires thermal/light stabilization expertise. Kolmar's FDA/cGMP rigor de-risks stability/compatibility challenges for humid climates.

Expected Benefits

Risk & Mitigation

Premium pricing typical; retinoid sensitivity in humid climates. Mitigation: Position as night serum with tolerance-building protocol; bundle with gentle moisturizer.

Next 3 Actions

  1. 1. RFQ dual prototype (retinol 0.3% vs retinaldehyde 0.1%); run 40°C stability testing
  2. 2. Add pregnancy caution and usage ramp instructions on Arabic/English label
  3. 3. Launch as kit with gel-cream moisturizer for enhanced tolerance
3

Unicare (UAE) + Acne Clearing Serum (F-AC1)

Why This Pairing

Fast UAE registration via Unicare's Dubai base, in-country Arabic labeling, and proximity to KSA reduces time-to-market. SA 2% + Niacinamide 4% stays in cosmetic classification per KSA guidelines.

Expected Benefits

  • • SA 2% cleanser shows lesion reduction and good tolerance
  • • Montaji registration familiarity reduces regulatory friction
  • • Arabic labeling handled locally vs outsourcing
  • • Lower MOQs typical of regional manufacturers

Risk & Mitigation

Limited clinical sophistication vs Tier-1 ODMs; SA may cause irritation. Mitigation: Combine with niacinamide for anti-inflammatory effect; position as gentle daily use.

Next 3 Actions

  1. 1. RFQ SA 2% gel-serum brief; request micro/heavy-metal testing per Montaji Annex 1
  2. 2. Prepare Montaji dossier (FSC, ingredient report with CAS/weights, lab tests)
  3. 3. Plan KSA eCosma notification once UAE artwork finalized

90-Day Implementation Plan

Project Timeline & Milestones

Week 0-2

Brief Finalization

  • • Lock formulation specs
  • • Approve claims guardrails
  • • Request RFQs from shortlist
  • • Arabic/English templates
Week 2-6

Sampling & Testing

  • • Pilot samples
  • • 40°C accelerated stability
  • • Heat/humidity sensory tests
  • • Finalize Arabic labels
Week 6-10

Registration Filing

  • • Submit Montaji/ECAS (UAE)
  • • Prepare SFDA eCosma (KSA)
  • • Device bundle compliance
  • • Production planning
Week 10-14

Launch Preparation

  • • Production slot booking
  • • KSA notification
  • • Retail pilot planning
  • • Dermatologist endorsements

Critical Compliance Guardrails

KSA Ingredient Limits

  • • Salicylic Acid: ≤2% leave-on (≤3% rinse-off hair) per SFDA classification
  • • Hydroquinone: Forbidden in cosmetics (drug classification)
  • • Tretinoin/Adapalene: Drug classification only
  • • Retinol: Monitor EU 0.3% RE precedent

UAE Testing Requirements

  • • Heavy Metals: Cd≤3ppm, Pb≤10ppm, As≤3ppm, Hg≤3ppm
  • • Microbiology: <10,000 CFU/g total bacteria
  • • AHA Products: pH≥3.5 retail, ≥3.0 professional
  • • Hydroquinone: Absent in whitening category

Key Manufacturer Contacts

COSMAX

Global ODM Leader

View Certifications

ISO 22716, MUI Halal

Global brand audits

Kolmar USA

FDA/cGMP Specialist

View Quality Systems

FDA Registered #1000221288

21 CFR 211 cGMP

Unicare Cosmetics

UAE Private Label

Visit Website

Dubai-based manufacturing

Arabic labeling in-house

For detailed regulatory documentation, clinical evidence, and complete manufacturer profiles, refer to the Master Dossier.

All regulatory links and clinical citations validated as of document generation date.